Biogen Inc. $BIIB Shares Sold by Teacher Retirement System of Texas

Key Points

• Teacher Retirement System of Texas cut its Biogen stake by 37.8% in Q4, selling 14,304 shares and leaving it with 23,489 shares valued at about $4.13 million.
• Insider Priya Singhal sold 2,660 shares at an average of $199.83 on Feb. 9, reducing her holding by 24.85%; insiders now own about 0.18% of the stock.
• Analysts hold a consensus "Hold" rating with an average target of $211.81 (14 Buys, 13 Holds, 1 Sell), while Biogen beat Q4 EPS and revenue estimates and set FY2026 guidance of 15.25–16.25 EPS.

Teacher Retirement System of Texas reduced its stake in Biogen Inc. (NASDAQ:BIIB - Free Report) by 37.8% in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 23,489 shares of the biotechnology company's stock after selling 14,304 shares during the period. Teacher Retirement System of Texas' holdings in Biogen were worth $4,134,000 as of its most recent filing with the Securities and Exchange Commission.

Other institutional investors and hedge funds have also made changes to their positions in the company. Accredited Wealth Management LLC increased its stake in shares of Biogen by 1,233.3% during the third quarter. Accredited Wealth Management LLC now owns 200 shares of the biotechnology company's stock valued at $28,000 after acquiring an additional 185 shares during the period. First Horizon Corp acquired a new stake in Biogen in the fourth quarter worth approximately $30,000. WFA of San Diego LLC acquired a new stake in Biogen in the second quarter worth approximately $32,000. True Wealth Design LLC lifted its holdings in shares of Biogen by 62.9% in the third quarter. True Wealth Design LLC now owns 233 shares of the biotechnology company's stock valued at $33,000 after buying an additional 90 shares during the period. Finally, GoalVest Advisory LLC bought a new position in shares of Biogen during the 4th quarter valued at about $35,000. 87.93% of the stock is currently owned by institutional investors.

Analyst Upgrades and Downgrades

A number of research firms recently weighed in on BIIB. Tudor Pickering set a $201.00 price target on Biogen in a research report on Monday, February 9th. Morgan Stanley upped their price objective on shares of Biogen from $190.00 to $200.00 and gave the company an "equal weight" rating in a research note on Friday, April 10th. Truist Financial decreased their target price on shares of Biogen from $193.00 to $189.00 and set a "hold" rating for the company in a report on Monday, April 13th. Argus raised shares of Biogen to a "hold" rating in a research report on Thursday, April 9th. Finally, TD Cowen upped their price target on shares of Biogen from $175.00 to $215.00 and gave the company a "buy" rating in a research report on Monday, February 9th. Fourteen research analysts have rated the stock with a Buy rating, thirteen have issued a Hold rating and one has issued a Sell rating to the company's stock. According to data from MarketBeat, the stock has a consensus rating of "Hold" and an average target price of $211.81.

Insider Buying and Selling

In other news, insider Priya Singhal sold 2,660 shares of the stock in a transaction dated Monday, February 9th. The stock was sold at an average price of $199.83, for a total transaction of $531,547.80. Following the transaction, the insider owned 8,043 shares of the company's stock, valued at approximately $1,607,232.69. This represents a 24.85% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. 0.18% of the stock is owned by insiders.

Biogen Price Performance

BIIB opened at $180.67 on Tuesday. The stock has a market cap of $26.52 billion, a price-to-earnings ratio of 20.51, a PEG ratio of 2.46 and a beta of 0.16. Biogen Inc. has a 1 year low of $115.25 and a 1 year high of $202.41. The company has a current ratio of 2.68, a quick ratio of 2.03 and a debt-to-equity ratio of 0.34. The stock has a fifty day moving average price of $184.81 and a 200 day moving average price of $175.58.

Biogen (NASDAQ:BIIB - Get Free Report) last issued its earnings results on Friday, February 6th. The biotechnology company reported $1.99 earnings per share for the quarter, topping the consensus estimate of $1.61 by $0.38. Biogen had a return on equity of 12.64% and a net margin of 13.07%.The company had revenue of $2.28 billion for the quarter, compared to analyst estimates of $2.21 billion. During the same period in the prior year, the firm posted $3.44 EPS. The business's revenue was down 7.2% compared to the same quarter last year. Biogen has set its FY 2026 guidance at 15.250-16.250 EPS. Analysts forecast that Biogen Inc. will post 15.76 EPS for the current fiscal year.

Biogen Company Profile

Biogen Inc is a multinational biotechnology company focused on discovering, developing and delivering therapies for neurological and neurodegenerative diseases. Headquartered in Cambridge, Massachusetts, the company has a longstanding emphasis on neuroscience, with research and commercial activities spanning multiple therapeutic areas including multiple sclerosis, spinal muscular atrophy and Alzheimer's disease. Biogen was founded in 1978 and has grown into a global biopharmaceutical firm with operations and commercial presence across North America, Europe, Japan and other international markets.

The company's marketed portfolio has historically included several well-known therapies for multiple sclerosis such as Avonex, Tysabri and Tecfidera, and it has pursued treatments for rare neurological conditions and genetic neuromuscular disorders.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.